Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

I-Tac Is A Dominant Chemokine In Controlling Skin Intragraft Inflammation Via Recruiting Cxcr3(+) Cells Into The Graft

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

Inflammasome Activation Involved in Early Inflammation Reaction after Liver Transplantation.

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Anti-CCL25 Antibody Prolongs Skin Allograft Survival by Blocking CCR9 Expression and Impairing Splenic T-Cell Function

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

CXCL9 and CXCL10 Accelerate Acute Transplant Rejection Mediated by Alloreactive Memory T Cells in a Mouse Retransplantation Model

Cxcl10 and Cxcl13 Expression Were Highly Up-Regulated in Peripheral Blood Mononuclear Cells in Acute Rejection and Poor Response to Anti-Rejection Therapy

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Inhibition of C-X-C Motif Chemokine 10 Reduces Graft Loss Mediated by Memory CD8(+) T Cells in a Rat Cardiac Re-Transplant Model

Decreased percentages of regulatory T cells are necessary to activate Th1-Th17-Th22 responses during acute rejection of the peripheral nerve xenotransplantation in mice

Monitoring Early-Stage Acute Rejection By Imaging Cxcr3-Positive Cell Infiltration: Evaluation Of (125)Iodine-Labeled Cxcl10

Peptide Nucleic Acid Antisense Prolongs Skin Allograft Survival by Means of Blockade of CXCR3 Expression Directing T Cells into Graft.

[Roles of CXCL9 and CXCL10 in Acute Rejection after Retransplantation in Mice].

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Noninvasive Allograft Imaging of Acute Rejection: Evaluation of 131 I-anti-CXCL10 mAb

Monitoring Early-Stage Acute Rejection by Imaging CXCR3-Positive Cell Infiltration: Evaluation of <SUP>125</SUP>Iodine-Labeled CXCL10

Cytotoxic T Lymphocyte-associated Protein 4 Acts on Local Draining Lymph Nodes in the Allogeneic Abdominal Skin Flap of a Rat Model to Extend Its Survival

Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin